

WDFY3 cell autonomously controls neuronal migration

Zachary Schaaf

UC Davis: University of California Davis

Lyvin Tat

UC Davis: University of California Davis

Noemi Cannizzaro

UC Davis: University of California Davis

Ralph Green

UC Davis: University of California Davis

Thomas Rüllicke

University of Veterinary Medicine Vienna: Veterinärmedizinische Universität Wien

Simon Hippenmeyer

Institute of biomedical sciences Vienna

Konstantinos Zarbalis (✉ kzarbalis@ucdavis.edu)

university of california davis <https://orcid.org/0000-0003-0681-2707>

Research

Keywords: WDFY3, cerebral cortex, neuronal migration, excitatory neurons, dendrites, dendritic spines

Posted Date: February 16th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1316167/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

WDFY3 cell autonomously controls neuronal migration

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Zachary A. Schaaf^{1,2}, Lyvin Tat¹, Noemi Cannizzaro¹, Ralph Green¹, Thomas Rüllicke³, Simon Hippenmeyer⁴, Konstantinos S. Zarbalis^{1,2,4}

¹ University of California at Davis, Department of Pathology and Laboratory Medicine

² Shriners Hospitals for Children Northern California

³ Department of Biomedical Sciences, University of Veterinary Medicine Vienna, 1210 Vienna, Austria

⁴ Institute of Science and Technology Austria, Am Campus 1, 3400 Klosterneuburg, Austria

⁵ UC Davis MIND Institute

16 **Abstract**

17

18 **Background**

19 Proper cerebral cortical development depends on the tightly orchestrated migration of newly born
20 neurons from the inner ventricular and subventricular zones to the outer cortical plate. Any
21 disturbance in this process during prenatal stages may lead to neuronal migration disorders
22 (NMDs), which can vary in extent from focal to global. Furthermore, NMDs show a substantial
23 comorbidity with other neurodevelopmental disorders, notably autism spectrum disorders (ASDs).
24 Our previous work demonstrated focal neuronal migration defects in mice carrying loss-of-
25 function alleles of the recognized autism risk gene *WDFY3*. However, the cellular origins of these
26 defects in *Wdfy3* mutant mice remain elusive and uncovering it will provide critical insight into
27 *WDFY3*-dependent disease pathology .

28 **Methods**

29 Here, in an effort to untangle the origins of NMDs in *Wdfy3^{lacZ}* mice, we employed mosaic analysis
30 with double markers (MADM). MADM technology enabled us to genetically distinctly track and
31 phenotypically analyze mutant and wild type cells concomitantly *in vivo* using immunofluorescent
32 techniques.

33 **Results**

34 We revealed a cell autonomous requirement of WDFY3 for accurate laminar positioning of cortical
35 projection neurons and elimination of mispositioned cells during early postnatal life. In addition,
36 we identified significant deviations in dendritic arborization, as well as synaptic density and
37 morphology between wild type, heterozygous, and homozygous *Wdfy3* mutant neurons in *Wdfy3*-
38 MADM reporter mice at postnatal stages.

39 **Limitations**

40 While *Wdfy3* mutant mice have provided valuable insight into prenatal aspects of ASD pathology
41 that remain inaccessible to investigation in humans, like most animal models, they do not a
42 perfectly replicate all aspects of human ASD biology. The lack of human data makes it
43 indeterminate whether morphological deviations described here apply to ASD patients.

44 **Conclusions**

45 Our genetic approach revealed several cell autonomous requirements of *Wdfy3* in neuronal
46 development that could underly the pathogenic mechanisms of *WDFY3*-related ASD conditions.
47 The results are also consistent with findings in other ASD animal models and patients and suggest
48 an important role for *Wdfy3* in regulating neuronal function and interconnectivity in postnatal life.

49

50

51 **Keywords**

52

53 *WDFY3*, cerebral cortex, neuronal migration, excitatory neurons, dendrites, dendritic spines

54

55

56 **Background**

57

58 During prenatal neurogenesis, newly born neurons are deployed from proliferative compartments
59 surrounding the ventricles towards the surface of the brain where they will settle into their proper
60 laminae and nuclei to form functional circuits [1-4]. Any disturbance of this tightly orchestrated
61 process can result in neuronal migration disorders (NMDs), birth defects with often devastating

62 consequences for affected individuals [5-9]. In the cerebral cortex, the primary site of many
63 NMDs, projection neurons are generated in the proliferative layers of the ventricular and
64 subventricular zones (VZ, SVZ) from radial glial cells (RGCs) and migrate radially to the pial
65 surface along radial glial fibers [2, 10, 11]. The earliest born neurons building the cortical plate
66 become the deepest layer of the cortex, and ensuing waves of newly born neurons migrate past
67 their predecessors forming layer upon layer below the superficial marginal zone. NMDs can range
68 from relatively mild cases such as focal cortical dysplasia with only limited migration anomalies
69 [12-14] to crippling diseases like lissencephaly, which display a reduction of gyri and a thickening
70 of gray matter over a large area or the entire cerebral cortex often leading to death in early
71 childhood [15, 16].

72 Interestingly, there is a pronounced comorbidity of NMDs with autism spectrum disorders
73 (ASDs), a fact that may contribute to the high prevalence of epilepsy in ASDs with co-diagnoses
74 reaching up to 40% of autism cases [17, 18]. Indeed, evidence from postmortem analysis of human
75 cases [19-23] and more recently from ASD mouse models [24, 25] strongly suggest that focal
76 cortical dysplasia are a common feature of the autistic brain, further strengthening the notion that
77 a subset of autism cases is rooted in dysregulations of prenatal neurogenesis.

78 We previously reported on the generation of *Wdfy3* mutant mice and on the
79 neurodevelopmental anomalies associated with *Wdfy3* loss-of-function [24]. *WDFY3* is an autism
80 risk gene and causative in a range of other neurodevelopmental disorders, including intellectual
81 disability and neurodevelopmental delay. Depending on the specific allele, heterozygous *WDFY3*
82 loss in humans is typically associated with macrocephaly, a feature faithfully modelled in
83 heterozygous and homozygous mutant mice. *Wdfy* genes (1-4) encode a small family of four
84 neuronally expressed, intracellular molecules associated with vesicular transport. *WDFY3* is a

85 member of the BEACH (**beige and CHS** proteins) protein family and contains, in addition to the
86 BEACH domain, a PH domain, five WD40 domains, and a C-terminal FYVE
87 (Fab1/YOTB/Vac1/EEA1) domain enabling its integration into vesicular membranes [32, 33].
88 Human WDFY3 has been shown to act as an autophagosomal scaffolding protein required for the
89 selective recruitment and degradation of macromolecular components such as aggregation-prone
90 proteins. Untangling the cellular causes underlying the morphological abnormalities in *Wdfy3*
91 mutant mice, we identified an essential role for WDFY3 in regulating a subset of RGC divisions
92 by promoting asymmetric differentiative over symmetric proliferative divisions. Consequently,
93 WDFY3 loss promotes self-renewing divisions in RGCs, transient expansion of the progenitor
94 pool, increased neurogenesis, and larger brains. In addition, homozygous *Wdfy3* mutation in mice
95 results in focal neuronal migration defects in which deep-layer neurons are typically mispositioned
96 in upper layers.

97 Radial migration of newly born cortical neurons is regulated by factors both intrinsic to the
98 migrating cells and/or extrinsic determined by the environment they navigate. Cell autonomous
99 effectors may involve cytoskeletal proteins that control cellular motility, such as neuronal tubulins
100 [26] and their regulators [27, 28] while cell non-autonomous effects may involve chemoattractants
101 expressed by surrounding cells, such as reelin [29]. WDFY3's cytosolic and possibly vesicular
102 localization within dividing progenitors suggested cell autonomous control over neuronal
103 migration, but in the absence of functional evidence remained speculative.

104 Here, we employed mosaic analysis with double markers (MADM) [30, 31] to trace the
105 laminar positioning of cortical projection neurons depending on *Wdfy3* genotype and quantitatively
106 assess mispositioned cells to endogenous *Wdfy3* loss. In addition, we addressed the question of
107 whether *Wdfy3* mutation has effects on neuronal morphology and circuit integration by evaluating

108 dendritic arborization, spine density and morphology. Our results demonstrate a true cell-
109 autonomous role of *Wdfy3* in regulating either aspect of neuronal laminar and circuit integration.

110

111

112 **Methods**

113

114 *Animal husbandry and genotyping.* Animals were housed in Plexiglas cages (55 x 33 x 19 cm) and
115 maintained in facilities approved by the Association for Assessment and Accreditation of
116 Laboratory Animal Care (AAALAC) International under standard laboratory conditions (21 ± 2
117 °C; 55 ± 5% humidity) on a 12 h light/dark cycle, with ad libitum access to both water and standard
118 rodent chow. Animal handling protocols were approved by the University of California at Davis
119 Institutional Animal Care and Use Committee overseen by the AAALAC International
120 accreditation program (latest accreditation in February 14th, 2020) and in compliance with the
121 ARRIVE [66] and NIH guidelines [67].

122 Mice carrying the *Wdfy3^{lacZ}* (*Wdfy3^{tm1a(KOMP)Mbp}*) allele were generated and genotyped as
123 previously described [24] and maintained on C57BL/6NJ background. To generate *Wdfy3^{lacZ}*-
124 MADM-5 mice, we crossed *Wdfy3^{+ / lacZ}* with homozygous MADM-5^{GT/GT} mice [31, 61].
125 Subsequently, compound heterozygous offspring was crossed with homozygous MADM-5^{TG/TG};
126 *Emx1^{Cre}* mice. The resulting offspring was genotyped for presence of *Wdfy3^{lacZ}*, *Emx1^{Cre}*, *GT*, and
127 *TG* cassettes and once pups positive for all markers identified they were processed for histological
128 analysis.

129

130 *Perfusion, brain collection, tissue preservation, and sectioning.* Mice collected for histological
131 analysis were transcardially perfused with phosphate-buffered saline (PBS) followed by 4%
132 paraformaldehyde (PFA) in PBS using a medical pump at a rate of 1 mL/min and immersed in 4%
133 PFA/PBS overnight at 4 °C. The next day skulls were washed with PBS, brains excavated,
134 cryopreserved through gradual sucrose immersion (15%, 30% in PBS), embedded in O.C.T.
135 compound (Fisher Healthcare), flash frozen on dry ice, and then transferred to -80 °C until
136 sectioning. O.C.T. embedded brains were coronally sectioned on a Leica CM-1950 cryostat at a
137 thickness of 30 µm. Sections were transferred onto glass slides (Thermo Fisher) and placed on a
138 slide warmer (Premiere XH-2004) at 40 °C for a minimum of 36 hours. Slides from the warmer
139 were then placed in a slide box and frozen at -80 °C until used.

140 Alternatively, dissected brains used for analysis of cell morphology were transferred into
141 PBS/0.1% NaN₃ until embedded in 4% agarose/PBS for immediate vibratome sectioning.
142 Agarose-embedded brains were submerged in ice-cold PBS and coronally sectioned at 200 µm on
143 a Leica VT-1000S vibratome. Sections were then transferred into 24 well plates with 1 mL of PBS
144 on ice and stored at 4 °C until use.

145

146 *Immunofluorescent labeling.* Slide-mounted sections were fixed with 4% PFA/PBS, followed by
147 three washes in PBS for 5 min each. For antigen retrieval, slides were submerged in 1x working
148 concentration of Diva Decloaker solution (Biocare Medical, Pacheco, CA) while heated in a
149 Decloaking Pressure Chamber at 90 °C for 30 min. Following this treatment, slides were washed
150 in PBS three times for 5 minutes and tissue blocked with 10 % donkey serum in PBS with 1%
151 Tritton X-100 (PBST) for 1 h at room temperature. After being washed with PBS, sections were
152 incubated with chosen primary antibodies for 18 h at 4 °C, subsequently washed five times for 10

153 min each with PBS, and secondary antibodies applied for 2 h at room temperature. After secondary
 154 incubation, slides were washed five times for 10 min each in PBS, and for 5 min submerged in a
 155 0.1% 4',6-diamidino-2-phenylindole (DAPI) (Thermo Fisher Scientific) to create a nuclear
 156 counterstain. After being washed twice 10 min each with PBS, sections were covered with
 157 Fluoromount-G (Thermo Fisher Scientific), mounted with cover glass (Thermo Fisher Scientific),
 158 and then allowed to dry in a dark ventilated area for a minimum of 20 h before being imaged.

159 Agarose embedded sections (200 μ m) were immunostained free floating on an orbital
 160 shaker (Labnet) at 30 rpm using the process described above while omitting antigen retrieval.
 161 Transfer of sections into washes, blocking, and incubation liquids were done using a paintbrush.
 162 Antibody incubation times were extended to account for increased tissue thickness compared with
 163 cryosections with primary incubation applied for 64 h at 4 °C and secondary incubation for 18 h
 164 at 4 °C. Sections were finally washed 6 times for 45 min each.

165 Post immunostaining, agarose coronal sections were immersed in ultra-fast optical clearing
 166 method (F.O.C.M.) solution for 15 minutes. Sections were then transferred to glass slides
 167 (thermofisher). Sections were covered in FOCM solution, and surrounded with Fluoromount-G
 168 (thermofisher) around the edges before coverslipping. Slides were allowed to dry in the dark for a
 169 minimum of 3 days before imaging.

170

171 *Primary antibodies used*

Target	Host Species	Manufacturer	Catalog #	Dilution (in PBST)
GFP	Chicken	Aves Labs	GFP-1010	1:200
RFP	Rabbit	Medical and Biological Laboratories	PM005	1:100

MCherry	Goat	Biorbyt	ORB11618	1:300
Brn2	Rabbit	Genetex	GTX114650	1:200
Ctip2	Rat	Abcam	AB18465	1:200
Tbr1	Rabbit	Abcam	AB31940	1:200
B-galactosidase	Rat	Medical and Biological Laboratories	M203-3	1:200
DAPI	n/a	Sigma Aldrich	MBD0015	1:1000

172

173 *Secondary antibodies used*

Target	Host				Dilution (in
Species	Species	Conjugate	Manufacturer	Catalog #	PBST)
Rat	Donkey	405	Jackson ImmunoResearch	712-475-153	1:200
Chicken	Donkey	488	Jackson ImmunoResearch	703-545-155	1:200
Goat	Donkey	594	Invitrogen	A-11058	1:200
Rabbit	Donkey	594	Invitrogen	A-21207	1:200
Rabbit	Donkey	647	Invitrogen	A-31573	1:200
Rat	Donkey	647	Abcam	AB150155	1:200

174

175

176 *Tissue clearing.* To increase clarity and microscope laser penetration of 200 μm thick sections used

177 for cell morphological analysis underwent overnight immersion at room temperature in ultrafast

178 optical clearing method (FOCM) solution; 30% (wt/vol), urea, 20% (wt/vol), D-sorbitol, and 5%

179 (wt/vol) glycerol dissolved in dimethylsulfoxide (DMSO) [35]. Sections were mounted on glass
180 slides, immersed in FOCM solution, covered with coverslips and imaged

181
182 *Microscopy and image processing.* To assess genotype distribution and laminar positioning
183 fluorescent confocal microscopy and image acquisition was performed on an inverted Nikon C1
184 microscope with associated software, typically at 10x magnification. Images used for cell
185 morphological analysis, including dendritic arbor and spine analysis were obtained on a Nikon A1
186 microscope with associated software. Subsequently, images were uploaded and cells counted in
187 NIS-Elements. Cellular Morphology was analyzed in FIJI using the Simple Neurite Tracer plugin.

188
189 *Statistical testing.* All data were from processed, analyzed, and graphical figures created in
190 Graphpad Prism 9. To remove suspected outliers, data were initially processed with the ROUT
191 outlier test (Q value = 1%). Applicable data were then tested for normality, variance, and standard
192 deviation before analysis. Lamination analysis was done using Fisher's exact test, population
193 analysis was done using a unpaired student's *t*-test, Sholl profile analysis was statistically
194 evaluated by two-way Analysis of Variance (ANOVA), followed by a Tukey's multiple
195 comparison test. Analysis of bouton density was done using a one-way ANOVA with multiple
196 comparisons while bouton subtype distribution analysis was done using a two-way ANOVA with
197 multiple comparisons. When applicable and reasonable to add, data are reported as a mean with
198 standard deviation. Bar graphs with replicates are reported as mean with standard error of the
199 mean. Results were considered to be statistically significant if $p \leq 0.05$. Individual data points
200 largely correspond to replicates of one brain. The extent of significance between groups is

201 indicated with one, two, three, or four asterisks if p -values were equal to or less than 0.05, 0.01,
202 0.001, or 0.0001, respectively.

203

204

205 **Results**

206

207 ***Wdfy3* mutant cells get disproportionately lost during early postnatal development in MADM** 208 **brains**

209 To test the efficacy of the *Wdfy3*-MADM system, we obtained brains of mice carrying all four
210 transgenic modifications (*Wdfy3^{lacZ}*, MADM-5^{GT}, MADM-5^{TG}, and *Emx1^{Cre}*) and immunolabeled
211 for endogenous tdT and eGFP expression. We opted to analyze three male and three female brains
212 each at two developmental stages, postnatal day (P)8, a time point at which developmental
213 neurogenesis is completed and all cortical layers are formed and distinguished, and P30, a time
214 point in which cell death associated with activity-dependent neuron elimination has largely faded
215 [32]. After imaging, sections of both stages revealed the expected sparse labeling of neurons and
216 astrocytes within all cortical layers with cells distributed across labels associated with the
217 anticipated recombination of fluorophore encoding cassettes. We detected red tdT⁺ cells expected
218 to be wild type (WT or +/+), green homozygous mutant GFP⁺ cells (*lacZ/lacZ*), and yellow
219 heterozygous tdT⁺/GFP⁺ cells (+/*lacZ*) (Fig. 1A, B). We proceeded to count all cells in ten sections
220 each of 3 male and 3 female brains per stage and converted the added numbers of each genotype
221 to ratios of a whole. In total, we counted at P8 685 tdT⁺ cells, 1,330 tdT⁺/GFP⁺ cells, and 658 GFP⁺
222 cells and at P30 614 tdT⁺ cells, 1,236 tdT⁺/GFP⁺ cells, and 262 GFP⁺ cells. Genotype populations
223 were compared across each other and between the two time points (P8 and P30). In P8 brains, the

224 distribution of GFP labeled homozygous mutant neurons was ~24%, likely due to cell death
225 significantly decreasing to ~12% in P30 brains (0.2368 ± 0.029 at P8 and 0.1216 ± 0.028 at P30;
226 $p < 0.0001$) (Fig. 1C). This relative decrease in mutant cells at P30 was accompanied by a
227 significant relative increase of both WT (0.2634 ± 0.026 at P8 and 0.2949 ± 0.010 at P30; $p = 0.02$)
228 and $+/\text{lacZ}$ cells (0.4998 ± 0.024 at P8 and 0.5835 ± 0.026 at P30; $p = 0.002$) (Fig. 1C). No
229 significant differences between the sexes were observed.

230

231 **Cortical lamination errors occur more frequently in *Wdfy3* homozygous mutant cells**

232 Realizing that early postnatal development is associated with the disproportionate loss of lacZ/lacZ
233 neurons, we proceeded to examine whether this loss is associated with the laminar positioning of
234 these neurons. We performed immunofluorescent labeling targeting endogenous tdT and eGFP
235 expression produced as a result of the MADM system, and colabeled for cortical layer markers
236 *Tbr1*, *Ctip2*, and *Brn2*, each at a time. *Tbr1* is predominantly expressed by layer VI neurons, *Ctip2*
237 by layer V neurons, and *Brn2* by layer II/III neurons respectively. The approach allowed us to
238 identify neurons of either fluorescent marker and genotype and, if positive for one of the cortical
239 layer markers, assess whether they were also correctly positioned within their respective layer.

240 Analyzing a total number of 730 cells of six brains (3 male, 3 female) at P8, mutant neurons
241 in *Wdfy3*-MADM mice were mispositioned more often than their WT counterpart. Tbr1^+ (VI)
242 mutant cells were correctly positioned in 46% of instances compared to ~91% of WT cells (WT
243 90.66%; lacZ/lacZ , 46%; $p < 0.0001$) (Fig. 2 A, G). Mutant Ctip2^+ cells (V) were also significantly
244 less often correctly positioned compared with WT cells (WT, 78.79%; lacZ/lacZ , 29.76%; $p <$
245 0.0001) (Fig. 2 C, H). The same observation was made with Brn2^+ cells (II/III) with mutant
246 neurons being significantly less often correctly located compared with WT neurons (WT, 89.78%;

247 *lacZ/lacZ*, 53.91%; $p < 0.0001$) (Fig. 2 E, I). Examining layer-specific positioning of 735 neurons
248 in six *Wdfy3*-MADM brains at P30 (3 male, 3 female), we found similar, but less exaggerated
249 discrepancies between WT and *lacZ/lacZ* neurons in P8 brains. *Tbr1*⁺ mutant cells were aligned in
250 the correct layer in ~63% of instances, compared to 87% for their WT counterpart (WT, 86.81%;
251 *lacZ/lacZ*, 62.82%; $p = 0.0003$) (Fig. 2 B, G). *Ctip2*⁺ mutant cells showed correct layer position
252 ~23% of the time compared with of ~65% WT cells (WT, 65.06%; *lacZ/lacZ*, 23.38%; $p < 0.0001$)
253 (Fig. 2 D, H). Lastly, *Brn2*⁺ mutant neurons were placed in the correct layer ~68% of the time,
254 compared with ~89% of the time for WT cells (WT, 88.52%; *lacZ/lacZ*, 67.98%; $p < 0.0001$) (Fig.
255 2 E, I).

256 Comparing the two stages (P8 and P30) with each other, the proportion of correctly aligned
257 *Tbr1*⁺ mutant neurons increased from ~46% at P8 to ~63% at P30 ($p = 0.0338$). Comparably, *Brn2*⁺
258 mutant neurons with correct layer position increased from ~54% in P8 brains, to ~68% in P30
259 brains ($p = 0.0095$), while *Ctip2*⁺ mutant neurons did not show significant differences between the
260 two developmental time points ($p = 0.3787$). Also, no significant differences were present for WT
261 neurons of any marker between the two stages and no significant deviations between the sexes
262 were recorded. Combining the data of all three markers together, ~45% of mutant neurons showed
263 correct laminar placement in P8 brains, increasing to ~59% in P30 brains (P8, 44.87%; P30,
264 58.58%; $p = 0.0003$). This relative increase likely reflects the selective elimination of
265 mispositioned *lacZ/lacZ* neurons during the examined postnatal period.

266

267 ***Wdfy3* mutant pyramidal neurons show decreased dendritic arborization**

268 Neurodevelopmental disorders, including autism, have been linked with changes in neuronal
269 morphology [33, 34]. In the MADM system, sparse labeling and the fact that cells are entirely

270 filled by the either fluorescent protein (eGFP or tdT), provided us with the option to examine
271 cellular morphological parameters and compare them between genotypes. We focused in particular
272 on the complexity of dendritic arbors and the density of dendritic spines or boutons. To capture
273 labeled neurons to the greatest possible extent, 200 μm thick sections of three male and three
274 female agarose-embedded *Wdfy3*-MADM brains were prepared and immuno-stained for eGFP and
275 tdT applying a free-floating protocol. Subsequently, sections were cleared by means of the ultrafast
276 optical clearing method (FOCM) [35] and mounted on microscope slides for deep imaging of
277 labeled cortical pyramidal neurons. Acquired z-stacks were traced to create Sholl profiles of 81
278 upper layer (II/III) and 81 deep layer (V/VI) cortical projection neurons of either genotype.

279 For either upper layer or deep layer neurons, both WT and heterozygous cells were more
280 complex than homozygous mutant cells while no noteworthy differences were observed between
281 sexes. For each genotype the mean number of intersections peaked at $\sim 100 \mu\text{m}$ from the soma and
282 significant differences between genotypes were mostly confined to distances of 15 μm to 200 μm
283 from the soma. The number of maximum intersections for deep layer WT neurons at $\sim 100 \mu\text{m}$ was
284 in average 18 while *lacZ/lacZ* neurons showed a peak average of 13.7 intersections ($p < 0.05 -$
285 0.0001). Heterozygous neurons were slightly but not significantly more complex than WT with an
286 average of 19.5 intersections at $\sim 100 \mu\text{m}$ distance from the soma ($+/lacZ$ vs. *lacZ/lacZ*, $p < 0.05 -$
287 0.001) (Fig. 3D). In upper layers, WT and $+/lacZ$ neurons showed near identical Sholl profiles
288 with peak intersections at $\sim 100 \mu\text{m}$ being on average 22.3 while *lacZ/lacZ* neurons showed a
289 highest average of 15.7 intersections at $\sim 100 \mu\text{m}$ from the soma (WT or $+/lacZ$ vs. *lacZ/lacZ*, $p <$
290 0.05 - 0.0001) (Fig. 3E).

291

292 ***Wdfy3* mutation increases synaptic spine density**

293 To assess dendritic spine density and subtype distribution, 200 μm sections of four male and three
294 female brains were immunolabeled and cleared via FOCM as described above. From acquired z-
295 stacks of 42 labeled cells of each genotype, 10 μm (in z-depth) regions of dendrites were then
296 extracted and dendritic spines counted while also tracking morphological features associated with
297 widely described subtypes, including filopodia, long thin, thin, stubby, mushroom, and branched
298 [36].

299 A decrease in *Wdfy3* gene dosage led to an overall increase in spine density. In WT neurons,
300 spine density averaged 0.29 spines per 1 μm . In heterozygous neurons, density significantly rose
301 to an average of 0.42 spines per μm . In *lacZ/lacZ* cells, we recorded an even higher density of 0.54
302 spines per μm while no sex-specific differences were observed in any genotype. (WT, $0.2907 \pm$
303 0.1111 ; *+lacZ*, 0.4188 ± 0.1004 ; *lacZ/lacZ* 0.5409 ± 0.1609 ; WT vs. *+lacZ* $p = 0.0286$; WT vs.
304 *lacZ/lacZ* $p = 0.0011$; *+lacZ* vs. *lacZ/lacZ*; $p = 0.0287$).

305 Dendritic spines can be distinguished by morphological criteria that associate with their
306 state of maturation and function. A well-replicated rank order of maturation distinguishes spines
307 that are filopodia, long thin, thin, stubby, mushroom shaped, and branched [36]. While assessing
308 overall spine density, we traced these different subtypes and converted counts to a percentage of a
309 whole to analyze distribution across genotypes. No significant differences between genotypes were
310 detected from a two-way analysis of variance (ANOVA), followed by a Tukey's multiple
311 comparison test (Fig. 4 H). Irrespective of genotype, the most prevalent spine types were long thin,
312 thin, and mushroom, comprising $\sim 90\%$ of all counted spines. In summary, we found *Wdfy3*
313 mutation to affect spine density in a gene dosage responsive manner, but to have no effect on spine
314 subtype distribution.

315

316

317 **Discussion**

318

319 Human *WDFY3* mutation will result in neurodevelopmental disorders, such as intellectual
320 disability, neurodevelopmental delay, and most frequently ASD associated with macrocephaly
321 [37-42]. While the megalencephalic phenotype has been faithfully replicated in both heterozygous
322 and homozygous *Wdfy3* mutant mice and its origins traced to altered RGC divisions [24, 42], the
323 developmental origins of the focal neuronal migration defects of homozygous mutant mice remain
324 uncertain. Migration defects of cortical projection neurons can have either intrinsic causes or be
325 the result of disrupted cell-environment interactions [4, 43, 44]. For instance, predominantly
326 intrinsic mechanisms underly lissencephaly caused by mutations in *LIS1 (PAFAH1B1)* or *DCX*
327 [45, 46]. LIS1 interacts with cytoplasmic dynein, a molecular motor required for microtubule-
328 based transport [47, 48]. *Lis1* knockdown in mice will block interkinetic nuclear migration, a
329 requirement for both RGC divisions and the motility of neuronal precursors that will derive from
330 them [49]. Similarly, mutations in neuronal tubulin *TUBA3 (Tuba1* in mice) will cause classic
331 lissencephaly [26]. Migration defects rooted in the loss of extrinsic signals have been extensively
332 studied in *reeler* mice that carry a mutation in *reelin (Reln)* [50, 51], a secreted glycoprotein
333 produced by Cajal-Retzius cells occupying the marginal zone during development [52]. Reln
334 signaling will activate an intracellular cascade of pathways that will promote migration and correct
335 positioning of cortical neurons critical components of which are Notch signaling [53] and
336 cadherin-mediated cell adhesion [54].

337 During mouse cortical neurogenesis, WDFY3 is predominantly expressed by dividing
338 RGCs, the pia, and diffusely in the intermediate zone [24]. By using *Emx1^{Cre}* as a driver, this study

339 sought to isolate cell autonomous vs. non cell autonomous effects of WDFY3 loss on radial
340 migration by conditionally limiting mutation to cortical projection neurons and their progenitors.
341 Our results strongly suggest the predominance of intrinsic WDFY3 activity guiding migration and
342 possibly survival of cortical neurons in the developing cortex. Indeed, while at P8 WT cells
343 overwhelmingly localize within the cortical layers specific to their marker identity, *lacZ/lacZ* cells
344 do so at significantly reduced frequency, typically at only half the rate of WT cells. At P30, we
345 found the ratio of *lacZ/lacZ* neurons that are correctly positioned within layers VI (*Tbr1*⁺) and
346 II/III (*Brn2*⁺) to be elevated compared to P8. This finding very likely points to corrective
347 mechanisms that are designed to eliminate misplaced and/or inadequately circuit-integrated
348 neurons from the developing brain via programmed cell death. Indeed, TUNEL analysis of mouse
349 parietal neocortical fields 1, 3 and 40 (largely corresponding to the area examined in the present
350 study) revealed cell death to peak at P4, but also to continue well into the third postnatal week [32].
351 These findings are supported by earlier studies that recorded in rodents an average of 30% neuronal
352 loss during the first postnatal month [55]. More recent work, however, describes a lesser,
353 approximately 12% loss of excitatory neocortical neurons, confined to the period between P2 and
354 P5 [56]. In light of our own data, it is conceivable that this period may be extended in case
355 pathological dysregulations require expanded corrections. That early postnatal neuronal apoptosis
356 is controlled by electrical activity appears also strongly supported by elegant work that associated
357 electrical activity patterns with neuronal death rates in two distinct cortical areas (M1 and S1) [57].
358 Thus, the suggestion that misplaced neurons may be especially targeted for removal as their
359 incorporation into physiologically functional networks is less likely, plausibly explains our
360 observations of progressively fewer *lacZ/lacZ* neurons located outside their correct layers.

361 Progressive *Wdfy3* gene loss results in concomitant increase in synaptic spine density. This

362 finding agrees with previous reports of added dendritic spine density in layer V pyramidal neurons
363 in the temporal lobe of ASD cases [58]. Apparently, augmented spine density in ASD is the result
364 of reduced developmental spine pruning precipitated by hyperactivated mTOR signaling and
365 resulting autophagy impairment [58]. Weakened autophagic function appears to be the molecular
366 cause of reduced spine elimination in ASD cases, as well as in *Tsc1/2*- and *Atg7*-deficient cortical
367 projection neurons, as analysis of mutant mice confirmed, drawing intriguing parallels to WDFY3
368 and its well-established role in regulating selective macroautophagy. While previous results did
369 not show diminished autophagic flux in brains of *Wdfy3* mutant mice, these studies were either
370 conducted in embryonic [24] or perinatal stages of homozygous mutants [59] and, due to perinatal
371 lethality of homozygous *Wdfy3* mutation, only in heterozygous adults [60]. Thus, subtle changes
372 in autophagy function caused by the synergy of homozygous *Wdfy3* loss and progressed age may
373 have eluded detection. Of course, it is possible that greater spine density in *Wdfy3* mutant cells is
374 caused by autophagy-independent mechanisms that currently remain elusive.

375 *Wdfy3*-MADM produced the predicted sparse labeling with WT red and *lacZ/lacZ* green
376 cells being generated in the same ratio while *+lacZ* yellow cells were twice as frequent as
377 homozygous genotypes. The rates of labeled cells are consistent with past findings and the
378 expectation that yellow cells being born out of G2-Z events, G1 recombination, and postmitotic
379 recombination (G0) will amount to approximately double as many cells as either red or green cells
380 [30, 31, 61]. The fact that yellow heterozygous cells are born at different timepoints poses
381 difficulties in comparing phenotypic features of this genotype to the other genotypes. However,
382 we noted that at least with respect to spine density heterozygous cells assumed an intermediate
383 phenotype between WT and homozygous mutant cells. This finding indicated dosage sensitivity
384 which may be relevant to human disease pathogenesis that is typically associated with

385 haploinsufficiency. In these situations additional, conceivably environmental, factors may be
386 responsible for full expression of the autistic phenotype [62-65].

387 Whether migration defects are present in typically heterozygous *WDFY3* patients remains
388 uncertain as of now. While MRI data for some patients are available with no evidence of focal
389 cortical dysplasia [42], limitations in resolution cannot provide certainty that small scale
390 lamination defects do not occur and may influence the clinical presentation in these patients. Our
391 work in mice found no mispositioned neurons in heterozygous mutants, but is also facing the
392 constraint that only two hypomorphic alleles have been examined in this respect, much fewer than
393 the number of known human alleles (49 alleles listed in denovo-db and 13 alleles reported in [42]).
394 Potential lamination defects have not been analyzed in other available *Wdfy3* mutant mouse lines
395 [59].

396

397

398 **Limitations**

399

400 *Wdfy3* mutant mice have been a valuable tool in understanding prenatal aspects of ASD pathology
401 that remain inaccessible to investigation in humans. However, like most animal models they are
402 not a perfect model in replicating all aspects of human ASD biology, as ASD-relevant behavioral
403 deviations in these mice remain inconclusive as of yet. It is also uncertain whether alterations in
404 neuronal morphology described here apply to ASD patients, considering the greater complexity of
405 the human brain and the lack of patient data.

406

407

408 **Conclusions**

409

410 In humans, *WDFY3* is a recognized autism risk gene associated with macrocephaly. *Wdfy3*
411 mutations in mice produce a complex phenotype of cortical maldevelopment including focal
412 neuronal migration defects of excitatory neurons. Using MADM technology in this study, we
413 arrive at the conclusion that these migration errors are driven by cell autonomous mechanisms that
414 act directly on mutant neurons and their progenitors rather than impaired cell-environment
415 interactions. In addition, we discovered alterations in mutant neuronal morphology consistent with
416 other reports documenting decreased dendritic arbor complexity but increased spine density in
417 autism mouse models and human cases. Our findings further underline the validity of *Wdfy3*
418 mutant mice as ASD models and point to the significance of changes at the chemical synapse in
419 ASD neuropathology.

420

421

422 **Abbreviations**

423

424 ANOVA, analysis of variance; ASD, autism spectrum disorders; GFP, green fluorescence protein;
425 VZ, ventricular zone; FOCM, ultrafast optical clearing method; MADM, mosaic analysis with
426 double markers; SVZ, subventricular zone; DAPI, 4',6-diamidino-2-phenylindole; tdT, tandem
427 dimer Tomato; WDFY3, WD repeat and FYVE domain containing 3; WT, wild type.

428

429

430 **Declarations**

431 **Ethics Approval**

432 Animals were handled in accordance with protocols approved by the University of California at
433 Davis Institutional Animal Care and Use Committee overseen by the AAALAC International
434 accreditation program (latest accreditation in February 14th, 2020) and in compliance with the
435 ARRIVE guidelines (Animal Research: Reporting in Vivo Experiments).

436 **Consent for publication**

437 Not applicable

438 **Availability of data and material**

439 Datasets analyzed and experimental tools such as transgenic mice used in the current study are
440 available from the corresponding author on reasonable request.

441 **Competing Interests**

442 The authors declare no competing interests.

443 **Funding**

444 This study was funded by NIMH R21MH115347 to KSZ. KSZ is further supported by Shriners
445 Hospitals for Children.

446 **Authors' contributions**

447 KSZ conceived the study and secured the funds. ZS, LT, and NC performed and analyzed
448 experiments. RG provided input on study design and edited the manuscript. TR and SH generated
449 and provided transgenic animals and participated in study design. All authors have read and
450 approved the final manuscript.

451 **Acknowledgments**

452 We would like to thank Angelo Harlan de Crescenzo for early contributions to this project.

453

454

455 **References**

456

- 457 1. Nadarajah, B. and J.G. Parnavelas, *Modes of neuronal migration in the developing cerebral*
458 *cortex*. Nat Rev Neurosci, 2002. **3**(6): p. 423-32.
- 459 2. Ayala, R., T. Shu, and L.H. Tsai, *Trekking across the brain: the journey of neuronal*
460 *migration*. Cell, 2007. **128**(1): p. 29-43.
- 461 3. Kwan, K.Y., N. Sestan, and E.S. Anton, *Transcriptional co-regulation of neuronal*
462 *migration and laminar identity in the neocortex*. Development, 2012. **139**(9): p. 1535-46.
- 463 4. Hippenmeyer, S., *Molecular pathways controlling the sequential steps of cortical*
464 *projection neuron migration*. Adv Exp Med Biol, 2014. **800**: p. 1-24.
- 465 5. Gleeson, J.G. and C.A. Walsh, *Neuronal migration disorders: from genetic diseases to*
466 *developmental mechanisms*. Trends Neurosci, 2000. **23**(8): p. 352-9.
- 467 6. Gupta, A., L.H. Tsai, and A. Wynshaw-Boris, *Life is a journey: a genetic look at*
468 *neocortical development*. Nat Rev Genet, 2002. **3**(5): p. 342-55.
- 469 7. Bielas, S., et al., *Cortical neuronal migration mutants suggest separate but intersecting*
470 *pathways*. Annu Rev Cell Dev Biol, 2004. **20**: p. 593-618.
- 471 8. Guerrini, R. and T. Filippi, *Neuronal migration disorders, genetics, and epileptogenesis*. J
472 Child Neurol, 2005. **20**(4): p. 287-99.
- 473 9. Guerrini, R. and E. Parrini, *Neuronal migration disorders*. Neurobiol Dis, 2010. **38**(2): p.
474 154-66.
- 475 10. Kriegstein, A.R. and S.C. Noctor, *Patterns of neuronal migration in the embryonic cortex*.
476 Trends Neurosci, 2004. **27**(7): p. 392-9.
- 477 11. Wu, Q., et al., *The dynamics of neuronal migration*. Adv Exp Med Biol, 2014. **800**: p. 25-
478 36.
- 479 12. Tassi, L., et al., *Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging*
480 *and surgical outcome*. Brain, 2002. **125**(Pt 8): p. 1719-32.
- 481 13. Krsek, P., et al., *Different features of histopathological subtypes of pediatric focal cortical*
482 *dysplasia*. Ann Neurol, 2008. **63**(6): p. 758-69.
- 483 14. Kabat, J. and P. Krol, *Focal cortical dysplasia - review*. Pol J Radiol, 2012. **77**(2): p. 35-
484 43.
- 485 15. Kato, M. and W.B. Dobyns, *Lissencephaly and the molecular basis of neuronal migration*.
486 Hum Mol Genet, 2003. **12 Spec No 1**: p. R89-96.
- 487 16. Fry, A.E., T.D. Cushion, and D.T. Pilz, *The genetics of lissencephaly*. Am J Med Genet C
488 Semin Med Genet, 2014. **166C**(2): p. 198-210.
- 489 17. Danielsson, S., et al., *Epilepsy in young adults with autism: a prospective population-based*
490 *follow-up study of 120 individuals diagnosed in childhood*. Epilepsia, 2005. **46**(6): p. 918-
491 23.
- 492 18. Mouridsen, S.E., B. Rich, and T. Isager, *A longitudinal study of epilepsy and other central*
493 *nervous system diseases in individuals with and without a history of infantile autism*. Brain
494 Dev, 2011. **33**(5): p. 361-6.
- 495 19. Bailey, A., et al., *A clinicopathological study of autism*. Brain, 1998. **121 (Pt 5)**: p. 889-
496 905.

- 497 20. Hutsler, J.J., T. Love, and H. Zhang, *Histological and magnetic resonance imaging*
498 *assessment of cortical layering and thickness in autism spectrum disorders*. Biol Psychiatry,
499 2007. **61**(4): p. 449-57.
- 500 21. Wegiel, J., et al., *The neuropathology of autism: defects of neurogenesis and neuronal*
501 *migration, and dysplastic changes*. Acta Neuropathol, 2010. **119**(6): p. 755-70.
- 502 22. Casanova, M.F., et al., *Focal cortical dysplasias in autism spectrum disorders*. Acta
503 Neuropathol Commun, 2013. **1**: p. 67.
- 504 23. Stoner, R., et al., *Patches of disorganization in the neocortex of children with autism*. N
505 Engl J Med, 2014. **370**(13): p. 1209-19.
- 506 24. Orosco, L.A., et al., *Loss of Wdfy3 in mice alters cerebral cortical neurogenesis reflecting*
507 *aspects of the autism pathology*. Nat Commun, 2014. **5**: p. 4692.
- 508 25. Choi, G.B., et al., *The maternal interleukin-17a pathway in mice promotes autism-like*
509 *phenotypes in offspring*. Science, 2016. **351**(6276): p. 933-9.
- 510 26. Keays, D.A., et al., *Mutations in alpha-tubulin cause abnormal neuronal migration in mice*
511 *and lissencephaly in humans*. Cell, 2007. **128**(1): p. 45-57.
- 512 27. Gleeson, J.G., et al., *Doublecortin, a brain-specific gene mutated in human X-linked*
513 *lissencephaly and double cortex syndrome, encodes a putative signaling protein*. Cell,
514 1998. **92**(1): p. 63-72.
- 515 28. Magen, D., et al., *Autosomal recessive lissencephaly with cerebellar hypoplasia is*
516 *associated with a loss-of-function mutation in CDK5*. Hum Genet, 2015. **134**(3): p. 305-
517 14.
- 518 29. Hong, S.E., et al., *Autosomal recessive lissencephaly with cerebellar hypoplasia is*
519 *associated with human RELN mutations*. Nat Genet, 2000. **26**(1): p. 93-6.
- 520 30. Zong, H., et al., *Mosaic analysis with double markers in mice*. Cell, 2005. **121**(3): p. 479-
521 92.
- 522 31. Contreras, X., et al., *A genome-wide library of MADM mice for single-cell genetic mosaic*
523 *analysis*. Cell Rep, 2021. **35**(12): p. 109274.
- 524 32. Verney, C., et al., *Independent controls for neocortical neuron production and histogenetic*
525 *cell death*. Dev Neurosci, 2000. **22**(1-2): p. 125-38.
- 526 33. Zoghbi, H.Y., *Postnatal neurodevelopmental disorders: meeting at the synapse?* Science,
527 2003. **302**(5646): p. 826-30.
- 528 34. Martinez-Cerdeno, V., *Dendrite and spine modifications in autism and related*
529 *neurodevelopmental disorders in patients and animal models*. Dev Neurobiol, 2017. **77**(4):
530 p. 393-404.
- 531 35. Zhu, X., et al., *Ultrafast optical clearing method for three-dimensional imaging with*
532 *cellular resolution*. Proc Natl Acad Sci U S A, 2019. **116**(23): p. 11480-11489.
- 533 36. Risher, W.C., et al., *Rapid Golgi analysis method for efficient and unbiased classification*
534 *of dendritic spines*. PLoS One, 2014. **9**(9): p. e107591.
- 535 37. Iossifov, I., et al., *De novo gene disruptions in children on the autistic spectrum*. Neuron,
536 2012. **74**(2): p. 285-99.
- 537 38. Iossifov, I., et al., *The contribution of de novo coding mutations to autism spectrum*
538 *disorder*. Nature, 2014. **515**(7526): p. 216-21.
- 539 39. Wang, T., et al., *De novo genic mutations among a Chinese autism spectrum disorder*
540 *cohort*. Nat Commun, 2016. **7**: p. 13316.


- 541 40. Stessman, H.A., et al., *Targeted sequencing identifies 91 neurodevelopmental-disorder*
542 *risk genes with autism and developmental-disability biases*. Nat Genet, 2017. **49**(4): p. 515-
543 526.
- 544 41. RK, C.Y., et al., *Whole genome sequencing resource identifies 18 new candidate genes for*
545 *autism spectrum disorder*. Nat Neurosci, 2017. **20**(4): p. 602-611.
- 546 42. Le Duc, D., et al., *Pathogenic WDFY3 variants cause neurodevelopmental disorders and*
547 *opposing effects on brain size*. Brain, 2019.
- 548 43. Evsyukova, I., C. Plestant, and E.S. Anton, *Integrative mechanisms of oriented neuronal*
549 *migration in the developing brain*. Annu Rev Cell Dev Biol, 2013. **29**: p. 299-353.
- 550 44. Hansen, A.H. and S. Hippenmeyer, *Non-Cell-Autonomous Mechanisms in Radial*
551 *Projection Neuron Migration in the Developing Cerebral Cortex*. Front Cell Dev Biol,
552 2020. **8**: p. 574382.
- 553 45. Dobyns, W.B., et al., *Lissencephaly. A human brain malformation associated with deletion*
554 *of the LIS1 gene located at chromosome 17p13*. JAMA, 1993. **270**(23): p. 2838-42.
- 555 46. Pilz, D.T., et al., *LIS1 and XLIS (DCX) mutations cause most classical lissencephaly, but*
556 *different patterns of malformation*. Hum Mol Genet, 1998. **7**(13): p. 2029-37.
- 557 47. Faulkner, N.E., et al., *A role for the lissencephaly gene LIS1 in mitosis and cytoplasmic*
558 *dynein function*. Nat Cell Biol, 2000. **2**(11): p. 784-91.
- 559 48. Smith, D.S., et al., *Regulation of cytoplasmic dynein behaviour and microtubule*
560 *organization by mammalian Lis1*. Nat Cell Biol, 2000. **2**(11): p. 767-75.
- 561 49. Tsai, J.W., et al., *LIS1 RNA interference blocks neural stem cell division, morphogenesis,*
562 *and motility at multiple stages*. J Cell Biol, 2005. **170**(6): p. 935-45.
- 563 50. D'Arcangelo, G., et al., *A protein related to extracellular matrix proteins deleted in the*
564 *mouse mutant reeler*. Nature, 1995. **374**(6524): p. 719-23.
- 565 51. Hirotsune, S., et al., *The reeler gene encodes a protein with an EGF-like motif expressed*
566 *by pioneer neurons*. Nat Genet, 1995. **10**(1): p. 77-83.
- 567 52. Ogawa, M., et al., *The reeler gene-associated antigen on Cajal-Retzius neurons is a crucial*
568 *molecule for laminar organization of cortical neurons*. Neuron, 1995. **14**(5): p. 899-912.
- 569 53. Hashimoto-Torii, K., et al., *Interaction between Reelin and Notch signaling regulates*
570 *neuronal migration in the cerebral cortex*. Neuron, 2008. **60**(2): p. 273-84.
- 571 54. Franco, S.J., et al., *Reelin regulates cadherin function via Dab1/Rap1 to control neuronal*
572 *migration and lamination in the neocortex*. Neuron, 2011. **69**(3): p. 482-97.
- 573 55. Nikolic, M., H.A. Gardner, and K.L. Tucker, *Postnatal neuronal apoptosis in the cerebral*
574 *cortex: physiological and pathophysiological mechanisms*. Neuroscience, 2013. **254**: p.
575 369-78.
- 576 56. Wong, F.K., et al., *Pyramidal cell regulation of interneuron survival sculpts cortical*
577 *networks*. Nature, 2018. **557**(7707): p. 668-673.
- 578 57. Blanquie, O., et al., *Electrical activity controls area-specific expression of neuronal*
579 *apoptosis in the mouse developing cerebral cortex*. Elife, 2017. **6**.
- 580 58. Tang, G., et al., *Loss of mTOR-dependent macroautophagy causes autistic-like synaptic*
581 *pruning deficits*. Neuron, 2014. **83**(5): p. 1131-43.
- 582 59. Dragich, J.M., et al., *Autophagy linked FYVE (Alfy/WDFY3) is required for establishing*
583 *neuronal connectivity in the mammalian brain*. Elife, 2016. **5**.
- 584 60. Napoli, E., et al., *Beyond autophagy: a novel role for autism-linked Wdfy3 in brain*
585 *mitophagy*. Sci Rep, 2018. **8**(1): p. 11348.

- 586 61. Amberg, N. and S. Hippenmeyer, *Genetic mosaic dissection of candidate genes in mice*
587 *using mosaic analysis with double markers*. STAR Protoc, 2021. **2**(4): p. 100939.
- 588 62. Chaste, P. and M. Leboyer, *Autism risk factors: genes, environment, and gene-environment*
589 *interactions*. Dialogues Clin Neurosci, 2012. **14**(3): p. 281-92.
- 590 63. Stamou, M., et al., *Neuronal connectivity as a convergent target of gene x environment*
591 *interactions that confer risk for Autism Spectrum Disorders*. Neurotoxicol Teratol, 2013.
592 **36**: p. 3-16.
- 593 64. Tordjman, S., et al., *Gene x Environment interactions in autism spectrum disorders: role*
594 *of epigenetic mechanisms*. Front Psychiatry, 2014. **5**: p. 53.
- 595 65. Courchesne, E., et al., *The ASD Living Biology: from cell proliferation to clinical*
596 *phenotype*. Mol Psychiatry, 2019. **24**(1): p. 88-107.
- 597 66. Percie du Sert, N., et al., *The ARRIVE guidelines 2.0: Updated guidelines for reporting*
598 *animal research*. J Cereb Blood Flow Metab, 2020. **40**(9): p. 1769-1777.
- 599 67. Council, N.R., *Committee for the Update of the Guide for the Care and Use of Laboratory*
600 *animals. Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use*
601 *of Laboratory Animals*. 2011, Washington (DC): National Academies Press (US) National
602 Academy of Sciences.
- 603

604

605 **Figures and figure legends**

606




607

608 **Figure 1. Genotype distributions in *Wdfy3*-MADM-5 cortex show specific loss of *Wdfy3*^{lacZ/lacZ}**
609 **cells at early postnatal stages.**

610 (A, B) TdT and GFP immunofluorescence of somatosensory cortex at P8 (A) and P30 (B) show
611 sparse neuronal and astrocytic labelling of expected genotypes, tdT⁺ cells are WT, GFP⁺ cells are
612 *lacZ/lacZ*, and tdT⁺/GFP⁺ cells are heterozygous. The bar diagram in C depicts the changes in
613 genotype distributions between the two developmental stages showing a significant relative
614 reduction of GFP⁺ (*lacZ/lacZ*) neurons ($p \leq 0.0001$) and significant relative increase in
615 heterozygous neurons (tdT⁺/GFP⁺; $p \leq 0.0001$). Scale bar is 250 μ m.

616

617




618

619 **Figure 2. Laminar distribution of labelled neurons reveals disproportionate misplacement**
 620 **of *lacZ/lacZ* neurons in *Wdfy3*-MADM-5 cortex.**

621 Immunofluorescent analysis reveals laminar positioning of WT and *lacZ/lacZ* neurons in relation
 622 to layers VI (Tbr1, **A, B**), V (Ctip2, **C, D**), and II-III (Brn2, **E, F**). (**G-I**) Quantifications of double-
 623 labelled cells reveal that, compared to WT, a significantly smaller percentage of *lacZ/lacZ* neurons
 624 is correctly positioned in their respective layer. The proportion of correctly placed layer VI (**G**)
 625 and layers II-III (**I**) *lacZ/lacZ* neurons significantly increases between P8 and P30, likely due to
 626 loss of misplaced neurons during early postnatal development. Tbr1⁺/tdT⁺ vs. Tbr1⁺/GFP⁺ at P8
 627 $p \leq 0.0001$ and at P30 $p \leq 0.001$. Ctip2⁺/tdT⁺ vs. Ctip2⁺/GFP⁺ at P8 $p \leq 0.0001$ and at P30
 628 $p \leq 0.0001$. Brn2⁺/tdT⁺ vs. Brn2⁺/GFP⁺ at P8 $p \leq 0.0001$ and at P30 $p \leq 0.0001$. Scale bar is 250
 629 μm .

630



632

633 **Figure 3. *Wdfy3* loss leads to reduced dendritic arborization.**

634 (A-C) TdT and GFP immunofluorescence of individual neurons shows changes in dendritic arbor

635 complexity. (D, E) Statistical analyses of Sholl profiles confirms significant changes of both deep

636 and upper layer wild type (+/+) or heterozygous neurons (+/*lacZ*) and *lacZ/lacZ* neurons.


637 Significant deviations are indicated by the heatmaps adjacent to the x-axes of the Sholl profiles

638 and *p*-values resolved on the key on the right. Scale bar is 100 μm.

639

640

641



642

643 **Figure 4. Dendritic spine density increases with progressive *Wdfy3* loss.**

644 (A-C) Representative 3D images of tdT and GFP immunolabelled neurons that are either wild type

645 (A), heterozygous (B), or homozygous (C) mutant. (D-F) High magnification images of individual

646 dendritic spines. (G) Quantified and statistically analyzed spine density (mean ± SD) in basal and

647 apical dendrites after the first bifurcation. Both *+/lacZ* ($p \leq 0.05$) and *lacZ/lacZ* ($p \leq 0.01$) neurons

648 show significantly higher bouton density compared with wild type. Homozygous mutant neurons

649 also display higher bouton density compared with heterozygous neurons ($p \leq 0.05$). Scale bar is 20

650 μm .

651